FDA gives AbbVie’s c-Met lung cancer ADC a breakthrough tag
pharmaphorum
JANUARY 5, 2022
Hutchmed’s drug is also being paired with Tagrisso and AZ’s PD-L1 blocker Imfinzi (durvalumab) in global registrational trials. The post FDA gives AbbVie’s c-Met lung cancer ADC a breakthrough tag appeared first on.
111 
Let's personalize your content